🇺🇸 FDA
Patent

US 12427148

Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

granted A61KA61K31/519A61K45/06

Quick answer

US patent 12427148 (Cancer treatment targeted to tumor adaptive responses to protein synthesis stress) held by The Regents of the University of California expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/519, A61K45/06, A61P, A61P35/02